Alnylam Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
CEOYvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees2,230
Employees2,230
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2002
Founded2002
Employees2,230
Employees2,230
ALNY Key Statistics
Market cap33.70B
Market cap33.70B
Price-Earnings ratio-123.44
Price-Earnings ratio-123.44
Dividend yield—
Dividend yield—
Average volume1.08M
Average volume1.08M
High today$271.29
High today$271.29
Low today$246.00
Low today$246.00
Open price$267.41
Open price$267.41
Volume1.70M
Volume1.70M
52 Week high$304.39
52 Week high$304.39
52 Week low$144.73
52 Week low$144.73
ALNY News
Simply Wall St 3d
Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats ExpectationsAlnylam Pharmaceuticals ( ) First Quarter 2025 Results Key Financial Results Revenue: US$594.2m (up 20% from 1Q 2024). Net loss: US$57.5m (loss narrowed by 1...
Benzinga 6d
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff RiskAlnylam Pharmaceuticals Inc ALNY on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03). The company repo...
Analyst ratings
74%
of 35 ratingsBuy
74.3%
Hold
22.9%
Sell
2.9%
People also own
Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.